Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head
Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi, after the French vaccine specialist announced it…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Mexico enlists Moderna to boost mRNA supply for respiratory diseases
The Mexican Government has struck a long-term agreement with Moderna that will see the drugmaker help the country boost its…
-
Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target
Gilead said it expects sales for its HIV portfolio to increase 6% in 2026 compared to 2025, spearheaded by growth…
-
AstraZeneca bets on continued oncology demand for 2026 growth
AstraZeneca expects profits to increase in 2026, as it counts on strong demand for its oncology portfolio continuing despite geopolitical…
-
Novo sues Hims & Hers despite Wegovy pill offering U-turn
Hims & Hers has abandoned plans to sell a compounded version of Novo Nordisk’s Wegovy (semaglutide) pill, though Novo and…
-
FDA’s commissioner vouchers prompt questions about award process
In June 2025, the US Food and Drug Administration (FDA) announced the Commissioner's National Priority Voucher (CNPV) pilot programme. The…
-
TrumpRx launches to slash drug prices for cash-paying US patients
President Donald Trump has unveiled his TrumpRx website, offering over 40 drugs at steeply discounted prices to cash-paying patients. The…
-
FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint
US Food and Drug Administration (FDA) Commissioner Marty Makary said the agency would target the mass-marketing of unapproved drugs amid…
-
Rare paediatric disease voucher programme makes long-awaited US return
After a lengthy period in regulatory limbo, the US Food and Drug Administration’s (FDA) rare paediatric disease priority review voucher…
-
Eli Lilly soars past expectations to hit 45% sales growth in 2025
Booming sales for GLP-1RA drugs fuelled a 45% surge in Eli Lilly’s revenue for 2025, cementing the drugmaker’s dominant position…